-
Dunkel, IJ, Cohen, K, Foreman, NK, Hargrave, D, Lassaletta, A, André, N, Hansford, JR, Hassall, T, Eyrich, M, Gururangan, S, et al.
IMMU-08. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: efficacy, safety, biomarker, and pharmacokinetic results from Checkmate 908.
Neuro-Oncology
24(Supplement_1)
:
i82 -i83
2022
view publication
-
Wood, P, Desai, J, Waldeck, K, Cain, J, Gottardo, N, Strong, R, Kinross, K, Carr, M, Jones, J, Wong, L, et al.
ATRT-17. A phase II study of continuous low dose panobinostat in paediatric patients with malignant rhabdoid tumours and atypical teratoid rhabdoid tumours..
Neuro-Oncology
24(Supplement_1)
:
i6 -i7
2022
view publication
-
Lamoureux, A-A, Fisher, M, Lemelle, L, Pfaff, E, Kramm, C, De Wilde, B, Kazanowska, B, Hutter, C, Pfister, SM, Sturm, D, et al.
HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion..
Neuro-Oncology
24(Supplement_1)
:
i61 -i62
2022
view publication
-
Gojo, J, Schmitt-Hoffner, F, Mauermann, M, von Hoff, K, Sill, M, Korshunov, A, Stichel, D, Capper, D, Tauziede-Espariat, A, Varlet, P, et al.
ETMR-06. Molecular and clinical characteristics of CNS tumors withBCOR(L1) fusion/internal tandem duplication.
Neuro-Oncology
24(Supplement_1)
:
i50 -i50
2022
view publication
-
Doz, F, van Tilburg, CM, Geoerger, B, Højgaard, M, Øra, I, Boni, V, Capra, M, Chisholm, J, Chung, HC, DuBois, SG, et al.
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors..
Neuro Oncol
24(6)
:
997 -1007
2022
view publication